ロード中...
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
MGCD0103 is an isotype-selective inhibitor of histone deacetylases (HDACs) targeted to isoforms 1, 2, 3, and 11. In a phase 1 study in patients with leukemia or myelodysplastic syndromes (MDS), MGCD0103 was administered orally 3 times weekly without interruption. Twenty-nine patients with a median a...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2008
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4081529/ https://ncbi.nlm.nih.gov/pubmed/18495956 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-10-115873 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|